AI Finds One Drug to Fight Resistant Pneumococcal Infections

Streptococcus pneumoniae, the bacterium responsible for severe pneumonia and meningitis, is increasingly difficult to treat as its resistance to conventional antibiotics grows. The rise in antimicrobial resistance is driving higher health‑care costs and mortality worldwide, prompting researchers to seek alternative therapeutic options. A recent study published in *Advanced Science* by Wiley reports that artificial intelligence can help identify existing, approved drugs that may be repurposed to combat this pathogen.

Using machine‑learning models trained on genomic and pharmacological data, the researchers screened thousands of compounds and pinpointed several that exhibit activity against S. pneumoniae in laboratory assays. The AI system prioritized drugs with known safety profiles, potentially accelerating their clinical evaluation. The study highlights the promise of computational drug discovery in addressing the urgent threat posed by resistant bacterial infections.

If the identified compounds prove effective in clinical trials, they could offer a rapid, cost‑effective addition to the limited arsenal against pneumococcal disease. The findings underscore the value of integrating advanced analytics into infectious‑disease research and may help curb the global burden of antibiotic‑resistant infections.